Immunogen (IMGN) 10.47 $IMGN
3 Beaten-Down Stocks Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 01, 12:45PM CDT
While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to a company's bad news, just as we often do when the market reacts to good...
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report).
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
Business Wire - Fri Aug 01, 5:30AM CDT
--a^' Conference Call Today at 8:00 am ETa^'
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Why ImmunoGen (IMGN) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:00AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:51AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as its shares rose nearly 9% on the day.
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014 Financial Results
Business Wire - Fri Jul 18, 5:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 1, 2014, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2014 and its guidance for its 2015 fiscal year. Management also will provide an update on the Company.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
4 Stocks Spiking on Big Volume
at The Street - Thu Jul 17, 8:10AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Critical Alerts For Royal Gold, Bed Bath & Beyond, ImmunoGen, ResMed, and Whirlpool Released By InvestorsObserver
PR Newswire - Tue Jul 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RGLD, BBBY, IMGN, RMD, and WHR.
3 Potentially Game-Changing Investigational Breast Cancer Drugs That May Soon Be Available
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 28, 9:32AM CDT
The grim reality of many types of cancer is that after decades of research we're still largely at a loss to explain what causes cancer in the first place and how to slow or stop its proliferation. While therapeutic improvements have been made in a...
Collaborations, Clinical Study Results, and Laboratory Inspection Clearance - Analyst Notes on Amgen, Regeneron, Lexicon, WuXi PharmaTech and ImmunoGen
PR Newswire - Wed Jun 25, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4088-100free.
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial
Recognitions, Shareholder Meeting Schedules, Partnerships, and Technical Updates - Analyst Notes on WellPoint, Medtronic, Auxilium, Sirona and ImmunoGen
PR Newswire - Tue Jun 17, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Medtronic, Inc. (NYSE: MDT), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Sirona Dental Systems Inc. (NASDAQ: SIRO) and ImmunoGen Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3788-100free.
CORRECTING and REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
Business Wire - Mon Jun 16, 9:14AM CDT
--IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
Business Wire - Mon Jun 16, 5:30AM CDT
--IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
3 Beaten-Down Stocks Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 01, 12:45PM CDT
While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to a company's bad news, just as we often do when the market reacts to good...
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report). ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
Business Wire - Fri Aug 01, 5:30AM CDT
--a^' Conference Call Today at 8:00 am ETa^'
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Why ImmunoGen (IMGN) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:00AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:51AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as its shares rose nearly 9% on the day.
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014 Financial Results
Business Wire - Fri Jul 18, 5:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 1, 2014, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2014 and its guidance for its 2015 fiscal year. Management also will provide an update on the Company.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
4 Stocks Spiking on Big Volume
at The Street - Thu Jul 17, 8:10AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Critical Alerts For Royal Gold, Bed Bath & Beyond, ImmunoGen, ResMed, and Whirlpool Released By InvestorsObserver
PR Newswire - Tue Jul 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RGLD, BBBY, IMGN, RMD, and WHR.
3 Potentially Game-Changing Investigational Breast Cancer Drugs That May Soon Be Available
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 28, 9:32AM CDT
The grim reality of many types of cancer is that after decades of research we're still largely at a loss to explain what causes cancer in the first place and how to slow or stop its proliferation. While therapeutic improvements have been made in a...
Collaborations, Clinical Study Results, and Laboratory Inspection Clearance - Analyst Notes on Amgen, Regeneron, Lexicon, WuXi PharmaTech and ImmunoGen
PR Newswire - Wed Jun 25, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4088-100free.
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial
Recognitions, Shareholder Meeting Schedules, Partnerships, and Technical Updates - Analyst Notes on WellPoint, Medtronic, Auxilium, Sirona and ImmunoGen
PR Newswire - Tue Jun 17, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Medtronic, Inc. (NYSE: MDT), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Sirona Dental Systems Inc. (NASDAQ: SIRO) and ImmunoGen Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3788-100free.
CORRECTING and REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
Business Wire - Mon Jun 16, 9:14AM CDT
--IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
Business Wire - Mon Jun 16, 5:30AM CDT
--IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
